Mental depression: Relation to different disease status, newer treatments and its association with COVID-19 pandemic (Review)
- Authors:
- Mohamed S. Abdel-Bakky
- Elham Amin
- Tarek M. Faris
- Ahmed A.H. Abdellatif
-
Affiliations: Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Qassim 51452, Saudi Arabia, Department of Pharmacognosy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt, Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Al-Azhar University, Cairo 11884, Egypt, Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraydah, Qassim 51452, Saudi Arabia - Published online on: October 8, 2021 https://doi.org/10.3892/mmr.2021.12479
- Article Number: 839
-
Copyright: © Abdel-Bakky et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Averina OV, Zorkina YA, Yunes RA, Kovtun AS, Ushakova VM, Morozova AY, Kostyuk GP, Danilenko VN and Chekhonin VP: Bacterial metabolites of human gut microbiota correlating with depression. Int J Mol Sci. 21:92342020. View Article : Google Scholar : PubMed/NCBI | |
|
Delgado PL and Moreno FA: Role of norepinephrine in depression. J Clin Psychiatry. 61 (Suppl 1):S5–S12. 2000.PubMed/NCBI | |
|
Zhang FF, Peng W, Sweeney JA, Jia ZY and Gong QY: Brain structure alterations in depression: Psychoradiological evidence. CNS Neurosci Ther. 24:994–1003. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Fox ME and Lobo MK: The molecular and cellular mechanisms of depression: A focus on reward circuitry. Mol Psychiatry. 24:1798–1815. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Muller JK and Leweke FM: Bipolar disorder: Clinical overview. Med Monatsschr Pharm. 39:363–369. 2016.PubMed/NCBI | |
|
American Psychiatric Association A and Association AP, . Diagnostic and Statistical Manual of Mental Dsorders (DSM-5). American Psychiatric Association; Washington, DC: 2013 | |
|
Assari S: Chronic medical conditions and major depressive disorder: Differential role of positive religious coping among African Americans, Caribbean blacks and non-hispanic whites. Int J Prev Med. 5:405–413. 2014.PubMed/NCBI | |
|
Devanand DP: Dysthymic disorder in the elderly population. Int Psychogeriatr. 26:39–48. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Molyneaux E, Poston L, Ashurst-Williams S and Howard LM: Obesity and mental disorders during pregnancy and postpartum: A systematic review and meta-analysis. Obstet Gynecol. 123:857–867. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sanassi LA: Seasonal affective disorder: Is there light at the end of the tunnel? JAAPA. 27:18–23. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gremaud-Heitz D, Riemenschneider A, Walter M, Sollberger D, Kuchenhoff J and Dammann G: Comorbid atypical depression in borderline personality disorder is common and correlated with anxiety-related psychopathology. Compr Psychiatry. 55:650–656. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Østergaard SD, Meyers BS, Flint AJ, Mulsant BH, Whyte EM, Ulbricht CM, Bech P and Rothschild AJ; STOP-PD Study Group, : Measuring psychotic depression. Acta Psychiatr Scand. 129:211–220. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Muralidharan K, Torres IJ, Silveira LE, Kozicky JM, Bücker J, Fernando N and Yatham LN: Impact of depressive episodes on cognitive deficits in early bipolar disorder: Data from the systematic treatment optimization programme for early mania (STOP-EM). Br J Psychiatry. 205:36–43. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Benti L, Manicavasagar V, Proudfoot J and Parker G: Identifying early indicators in bipolar disorder: A qualitative study. Psychiatr Q. 85:143–153. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Harnic D, Pompili M, Innamorati M, Erbuto D, Lamis DA, Bria P, Girardi P and Janiri L: Affective temperament and attachment in adulthood in patients with bipolar disorder and cyclothymia. Compr Psychiatry. 55:999–1006. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Craner JR, Sigmon ST, Martinson AA and McGillicuddy ML: Premenstrual disorders and rumination. J Clin Psychol. 70:32–47. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Simpson T and Ivey J: Pediatric management problems. Situational depression. Pediatr Nurs. 31:312–313. 2005.PubMed/NCBI | |
|
Jorm AF, Christensen H, Griffiths KM and Rodgers B: Effectiveness of complementary and self-help treatments for depression. Med J Aust. 176:S84–S96. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Baldwin DS: Unmet needs in the pharmacological management of depression. Hum Psychopharmacol. 16:S93–S99. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hossain MM, Tasnim S, Sultana A, Faizah F, Mazumder H, Zou L, McKyer ELJ, Ahmed HU and Ma P: Epidemiology of mental health problems in COVID-19: A review. F1000Res. 9:6362020. View Article : Google Scholar : PubMed/NCBI | |
|
Pedersen CB, Mors O, Bertelsen A, Waltoft BL, Agerbo E, McGrath JJ, Mortensen PB and Eaton WW: A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry. 71:573–581. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mojtabai R, Olfson M and Han B: National trends in the prevalence and treatment of depression in adolescents and young adults. Pediatrics. 138:e201618782016. View Article : Google Scholar : PubMed/NCBI | |
|
Substance Abuse and Mental Health Services Association, . 2018. | |
|
Duffy ME, Twenge JM and Joiner TE: Trends in mood and anxiety symptoms and suicide-related outcomes among U.S. undergraduates, 2007–2018: Evidence from two national surveys. J Adolesc Health. 65:590–598. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kuehner C: Why is depression more common among women than among men? Lancet Psychiatry. 4:146–158. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Borges G, Bromet EJ, Bruffaerts R, de Girolamo G, de Graaf R, Gureje O, et al: Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. Lancet. 370:841–850. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Katon W and Sullivan MD: Depression and chronic medical illness. J Clin Psychiatry. 51 (Suppl):S3–S14. 1990.PubMed/NCBI | |
|
Lebowitz BD, Pearson JL, Schneider LS, Reynolds CF III, Alexopoulos GS, Bruce ML, Conwell Y, Katz IR, Meyers BS, Morrison MF, et al: Diagnosis and treatment of depression in late life. Consensus statement update. JAMA. 278:1186–1190. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Slavich GM and Irwin MR: From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. Psychol Bull. 140:774–815. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, et al: Depression as a risk factor for Alzheimer disease: The MIRAGE study. Arch Neurol. 60:753–759. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ramasubbu R and Patten SB: Effect of depression on stroke morbidity and mortality. Can J Psychiatry. 48:250–257. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hesdorffer DC, Hauser WA, Annegers JF and Cascino G: Major depression is a risk factor for seizures in older adults. Ann Neurol. 47:246–249. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Nouwen A, Lloyd CE and Pouwer F: Depression and type 2 diabetes over the lifespan: A meta-analysis. Response to Mezuk et al. Diabetes Care. 32:e56–e57. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Penninx BW, Guralnik JM, Pahor M, Ferrucci L, Cerhan JR, Wallace RB and Havlik RJ: Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst. 90:1888–1893. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Keller MB, Hirschfeld RM, Demyttenaere K and Baldwin DS: Optimizing outcomes in depression: Focus on antidepressant compliance. Int Clin Psychopharmacol. 17:265–271. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Bouwman V, Adriaanse MC, van't Riet E, Snoek FJ, Dekker JM and Nijpels G: Depression, anxiety and glucose metabolism in the general dutch population: The New Hoorn Study. PLoS One. 5:e99712010. View Article : Google Scholar : PubMed/NCBI | |
|
Shelton RC and Miller AH: Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression. Prog Neurobiol. 91:275–299. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Shirey K, Manyara SM, Atwoli L, Tomlin R, Gakinya B, Cheng S, Kamano J, Laktabai J and Pastakia S: Symptoms of depression among patients attending a diabetes care clinic in rural western Kenya. J Clin Transl Endocrinol. 2:51–54. 2015.PubMed/NCBI | |
|
Häfner S, Baumert J, Emeny RT, Lacruz ME, Thorand B, Herder C, Koenig W, Rupprecht R and Ladwig KH: Sleep disturbances and depressed mood: A harmful combination associated with increased leptin levels in women with normal weight. Biol Psychol. 89:163–169. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Becker C, Zeau B, Rivat C, Blugeot A, Hamon M and Benoliel JJ: Repeated social defeat-induced depression-like behavioral and biological alterations in rats: Involvement of cholecystokinin. Mol Psychiatry. 13:1079–1092. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kozlovsky N, Matar MA, Kaplan Z, Zohar J and Cohen H: The role of the galaninergic system in modulating stress-related responses in an animal model of posttraumatic stress disorder. Biol Psychiatry. 65:383–391. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cline BH, Steinbusch HW, Malin D, Revishchin AV, Pavlova GV, Cespuglio R and Strekalova T: The neuronal insulin sensitizer dicholine succinate reduces stress-induced depressive traits and memory deficit: Possible role of insulin-like growth factor 2. BMC Neurosci. 13:1102012. View Article : Google Scholar : PubMed/NCBI | |
|
Roesler R, Henriques JA and Schwartsmann G: Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurological disorders. CNS Neurol Disord Drug Targets. 5:197–204. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Musselman DL and Nemeroff CB: Depression and endocrine disorders: Focus on the thyroid and adrenal system. Br J Psychiatry Suppl. 123–128. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Frey A, Lampert A, Dietz K, Striebich S, Locher C, Fedorenko O, Möhle R, Gallinat J, Lang F and Lang UE: Thyrotropin serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychobiology. 56:123–126. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bahls SC and de Carvalho GA: The relation between thyroid function and depression: A review. Braz J Psychiatry. 26:41–49. 2004.(In Portuguese). View Article : Google Scholar : PubMed/NCBI | |
|
Cleare AJ, McGregor A and O'Keane V: Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clin Endocrinol (Oxf). 43:713–719. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Holtzheimer PE III and Nemeroff CB: Future prospects in depression research. Dialogues Clin Neurosci. 8:175–189. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Banki CM, Bissette G, Arato M, O'Connor L and Nemeroff CB: CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry. 144:873–877. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Lippi G, Montagnana M, Favaloro EJ and Franchini M: Mental depression and cardiovascular disease: A multifaceted, bidirectional association. Semin Thromb Hemost. 35:325–336. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tiemeier H, van Dijck W, Hofman A, Witteman JC, Stijnen T and Breteler MM: Relationship between atherosclerosis and late-life depression: The rotterdam study. Arch Gen Psychiatry. 61:369–376. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Nemeroff CB and Goldschmidt-Clermont PJ: Heartache and heartbreak-the link between depression and cardiovascular disease. Nat Rev Cardiol. 9:526–539. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Geiser F, Meier C, Wegener I, Imbierowicz K, Conrad R, Liedtke R, Oldenburg J and Harbrecht U: Association between anxiety and factors of coagulation and fibrinolysis. Psychother Psychosom. 77:377–383. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Nemeroff CB and Musselman DL: Are platelets the link between depression and ischemic heart disease? Am Heart J. 140 (Suppl 4):S57–S62. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Stafford L and Berk M: The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: Proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry. 72:1229–1235. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jin K, Zhu Y, Sun Y, Mao XO, Xie L and Greenberg DA: Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA. 99:11946–11950. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Warner-Schmidt JL and Duman RS: VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA. 104:4647–4652. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kahl KG, Bens S, Ziegler K, Rudolf S, Kordon A, Dibbelt L and Schweiger U: Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology. 34:353–357. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Nakataki M, Iga J, Numata S, Yoshimoto E, Kodera K, Watanabe SY, Song H, Ueno S and Ohmori T: Gene expression and association analysis of the epithelial membrane protein 1 gene in major depressive disorder in the Japanese population. Neurosci Lett. 489:126–130. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Dantzer R: Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am. 29:247–264. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M and Kamalipour A: Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. Depress Anxiety. 26:607–611. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, et al: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 11:680–684. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, Bowden CL and Soares JC: Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 23:87–94. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar B, Kuhad A and Chopra K: Neuropsychopharmacological effect of sesamol in unpredictable chronic mild stress model of depression: Behavioral and biochemical evidences. Psychopharmacology (Berl). 214:819–828. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lau BW, Ren C, Yang J, Yan SW, Chang RC, Pu M and So KF: Light deprivation induces depression-like behavior and suppresses neurogenesis in diurnal mongolian gerbil (Meriones unguiculatus). Cell Transplant. 20:871–881. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ljubicić D, Stipcević T, Pivac N, Jakovljević M and Mück-Seler D: The influence of daylight exposure on platelet 5-HT levels in patients with major depression and schizophrenia. J Photochem Photobiol B. 89:63–69. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ubbenhorst A, Striebich S, Lang F and Lang UE: Exploring the relationship between vitamin D and basic personality traits. Psychopharmacology (Berl). 215:733–737. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
LeBourgeois MK, Carskadon MA, Akacem LD, Simpkin CT, Wright KP Jr, Achermann P and Jenni OG: Circadian phase and its relationship to nighttime sleep in toddlers. J Biol Rhythms. 28:322–331. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Almeida OP, Marsh K, Alfonso H, Flicker L, Davis TM and Hankey GJ: B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial. Ann Neurol. 68:503–510. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sanhueza C, Ryan L and Foxcroft DR: Diet and the risk of unipolar depression in adults: Systematic review of cohort studies. J Hum Nutr Diet. 26:56–70. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lazarou C and Kouta C: The role of nurses in the prevention and management of obesity. Br J Nurs. 19:641–647. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Papakostas GI, Mischoulon D, Shyu I, Alpert JE and Fava M: S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: A double-blind, randomized clinical trial. Am J Psychiatry. 167:942–948. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
O'Shea RD: Roles and regulation of glutamate transporters in the central nervous system. Clin Exp Pharmacol Physiol. 29:1018–1023. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Erecińska M and Silver IA: Metabolism and role of glutamate in mammalian brain. Prog Neurobiol. 35:245–296. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL and Sanacora G: Glial pathology in an animal model of depression: Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry. 15:501–511. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gourley SL, Espitia JW, Sanacora G and Taylor JR: Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacology (Berl). 219:805–814. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, et al: A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 67:793–802. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lauterbach EC: Dextromethorphan as a potential rapid-acting antidepressant. Med Hypotheses. 76:717–719. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Drevets WC and Furey ML: Replication of scopolamine's antidepressant efficacy in major depressive disorder: A randomized, placebo-controlled clinical trial. Biol Psychiatry. 67:432–438. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Furey ML and Drevets WC: Antidepressant efficacy of the antimuscarinic drug scopolamine: A randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 63:1121–1129. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sawada T and Yokoi K: Effect of zinc supplementation on mood states in young women: A pilot study. Eur J Clin Nutr. 64:331–333. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Barragán-Rodríguez L, Rodríguez-Morán M and Guerrero-Romero F: Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: A randomized, equivalent trial. Magnes Res. 21:218–223. 2008.PubMed/NCBI | |
|
Schmidt HD and Duman RS: The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol. 18:391–418. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Schmidt HD, Shelton RC and Duman RS: Functional biomarkers of depression: Diagnosis, treatment, and pathophysiology. Neuropsychopharmacology. 36:2375–2394. 2011. View Article : Google Scholar : PubMed/NCBIPubMed/NCBI | |
|
Pittenger C and Duman RS: Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology. 33:88–109. 2008. View Article : Google Scholar : PubMed/NCBIPubMed/NCBI | |
|
Schinder AF and Poo M: The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci. 23:639–645. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Aydemir O, Deveci A and Taneli F: The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: A preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 29:261–265. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Sen S, Duman R and Sanacora G: Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications. Biol Psychiatry. 64:527–532. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cattaneo A, Sesta A, Calabrese F, Nielsen G, Riva MA and Gennarelli M: The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment. Neuropsychopharmacology. 35:1423–1428. 2010. View Article : Google Scholar : PubMed/NCBIPubMed/NCBI | |
|
Hunsberger JG, Newton SS, Bennett AH, Duman CH, Russell DS, Salton SR and Duman RS: Antidepressant actions of the exercise-regulated gene VGF. Nat Med. 13:1476–1482. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hellweg R, Lang UE, Nagel M and Baumgartner A: Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats. Mol Psychiatry. 7:604–608. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
von Richthofen S, Lang UE and Hellweg R: Effects of different kinds of acute stress on nerve growth factor content in rat brain. Brain Res. 987:207–213. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Rosa AR, Frey BN, Andreazza AC, Ceresér KM, Cunha AB, Quevedo J, Santin A, Gottfried C, Gonçalves CA, Vieta E and Kapczinski F: Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neurosci Lett. 407:146–150. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Scapagnini G, Davinelli S, Drago F, De Lorenzo A and Oriani G: Antioxidants as antidepressants: Fact or fiction? CNS Drugs. 26:477–490. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Leonard B and Maes M: Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 36:764–785. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lopresti AL, Hood SD and Drummond PD: A review of lifestyle factors that contribute to important pathways associated with major depression: Diet, sleep and exercise. J Affect Disord. 148:12–27. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Galecki P: Oxidative stress in depression. Systems Biology of Free Radicals and Antioxidants. Laher I: Springer; Berlin: pp. 2369–2395. 2014, View Article : Google Scholar | |
|
Lukic I, Mitic M, Djordjevic J, Tatalovic N, Bozovic N, Soldatovic I, Mihaljevic M, Pavlovic Z, Radojcic MB, Maric NP and Adzic M: Lymphocyte levels of redox-sensitive transcription factors and antioxidative enzymes as indicators of pro-oxidative state in depressive patients. Neuropsychobiology. 70:1–9. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Maes M, Galecki P, Chang YS and Berk M: A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry. 35:676–692. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Halliwell B: Free radicals and antioxidants-quo vadis? Trends Pharmacol Sci. 32:125–130. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sperner-Unterweger B, Kohl C and Fuchs D: Immune changes and neurotransmitters: Possible interactions in depression? Prog Neuropsychopharmacol Biol Psychiatry. 48:268–276. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kudlow P, Cha DS, Carvalho AF and McIntyre RS: Nitric oxide and major depressive disorder: Pathophysiology and treatment implications. Curr Mol Med. 16:206–215. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Steinert JR, Chernova T and Forsythe ID: Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist. 16:435–452. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tobe EH: Mitochondrial dysfunction, oxidative stress, and major depressive disorder. Neuropsychiatr Dis Treat. 9:567–573. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gandal MJ, Haney JR, Parikshak NN, Leppa V, Ramaswami G, Hartl C, Schork AJ, Appadurai V, Buil A, Werge TM, et al: Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Focus (Am Psychiatr Publ). 17:66–72. 2019.PubMed/NCBI | |
|
Gandal MJ, Haney JR, Parikshak NN, Leppa V, Ramaswami G, Hartl C, Schork AJ, Appadurai V, Buil A, Werge TM, et al: Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science. 359:693–697. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Dean B: Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: Evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol. 14:997–1012. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Akula N, Barb J, Jiang X, Wendland JR, Choi KH, Sen SK, Hou L, Chen DT, Laje G, Johnson K, et al: RNA-sequencing of the brain transcriptome implicates dysregulation of neuroplasticity, circadian rhythms and GTPase binding in bipolar disorder. Mol Psychiatry. 19:1179–1185. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Z, Xu J, Chen J, Kim S, Reimers M, Bacanu SA, Yu H, Liu C, Sun J, Wang Q, et al: Transcriptome sequencing and genome-wide association analyses reveal lysosomal function and actin cytoskeleton remodeling in schizophrenia and bipolar disorder. Mol Psychiatry. 20:563–572. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bernard R, Kerman IA, Thompson RC, Jones EG, Bunney WE, Barchas JD, Schatzberg AF, Myers RM, Akil H and Watson SJ: Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol Psychiatry. 16:634–646. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Feyissa AM, Chandran A, Stockmeier CA and Karolewicz B: Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 33:70–75. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kang HJ, Adams DH, Simen A, Simen BB, Rajkowska G, Stockmeier CA, Overholser JC, Meltzer HY, Jurjus GJ, Konick LC, et al: Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. J Neurosci. 27:13329–13340. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Labonté B, Engmann O, Purushothaman I, Menard C, Wang J, Tan C, Scarpa JR, Moy G, Loh YE, Cahill M, et al: Sex-specific transcriptional signatures in human depression. Nat Med. 23:1102–1111. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ando V, Claridge G and Clark K: Psychotic traits in comedians. Br J Psychiatry. 204:341–345. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Heyman E, Gamelin FX, Goekint M, Piscitelli F, Roelands B, Leclair E, Di Marzo V and Meeusen R: Intense exercise increases circulating endocannabinoid and BDNF levels in humans-possible implications for reward and depression. Psychoneuroendocrinology. 37:844–851. 2012. View Article : Google Scholar : PubMed/NCBIPubMed/NCBI | |
|
Blanke U and te Wildt B: Depressive disorders in the context of biographical and historical changes-experiences within a psychiatric outpatient service. Psychiatr Prax. 34 (Suppl 3):S269–S272. 2007.(In German). View Article : Google Scholar : PubMed/NCBI | |
|
Wang SJ and Chen MY: The effects of sunlight exposure therapy on the improvement of depression and quality of life in post-stroke patients: A RCT study. Heliyon. 6:e043792020. View Article : Google Scholar : PubMed/NCBI | |
|
Bouron A and Lorrain E: Cellular and molecular effects of the antidepressant hyperforin on brain cells: Review of the literature. Encephale. 40:108–113. 2014.(In French). View Article : Google Scholar : PubMed/NCBI | |
|
Owens MJ, Morgan WN, Plott SJ and Nemeroff CB: Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 283:1305–1322. 1997.PubMed/NCBI | |
|
Menkes D, Bosanac P and Castle D: MAOIs-does the evidence warrant their resurrection? Australas Psychiatry. 24:371–373. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Dale E, Bang-Andersen B and Sánchez C: Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem Pharmacol. 95:81–97. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma H, Santra S and Dutta A: Triple reuptake inhibitors as potential next-generation antidepressants: A new hope? Future Med Chem. 7:2385–2406. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C and Barbui C: Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 10:CD0065332012.PubMed/NCBI | |
|
Parker L, Huelin R, Khankhel Z, Wasiak R and Mould J: A systematic review of pharmacoeconomic studies for pregabalin. Pain Pract. 15:82–94. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Y, Huang Y, Song M, Zhang Z, Liang Z and Deng X: Anticonvulsive activity of duloxetine: A new choice for the epileptic patients with depression. Pak J Pharm Sci. 32:997–1003. 2019.PubMed/NCBI | |
|
Kumar R, Sinha VR, Dahiya L and Sarwal A: Transdermal delivery of duloxetine-sulfobutylether-β-cyclodextrin complex for effective management of depression. Int J Pharm. 594:1201292021. View Article : Google Scholar : PubMed/NCBI | |
|
Ashby CR Jr, Kehne JH, Bartoszyk GD, Renda MJ, Athanasiou M, Pierz KA and Seyfried CA: Electrophysiological evidence for rapid 5-HT1A autoreceptor inhibition by vilazodone, a 5-HT1A receptor partial agonist and 5-HT reuptake inhibitor. Eur J Pharmacol. 714:359–365. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bathla M and Anjum S: A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression. Indian J Pharmacol. 52:10–15. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Hashimoto K, Malchow B, Falkai P and Schmitt A: Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci. 263:367–377. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Burgdorf J, Zhang XL, Weiss C, Matthews E, Disterhoft JF, Stanton PK and Moskal JR: The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol Aging. 32:698–706. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mørk A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M and Sanchez C: Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 105:41–50. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Katona C, Hansen T and Olsen CK: A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 27:215–223. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao L: Agomelatine for postpartum depression and breastfeeding. Ther Adv Psychopharmacol. 11:204512532110221722021. View Article : Google Scholar : PubMed/NCBI | |
|
de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C and Millan MJ: Agomelatine, the first melatonergic antidepressant: Discovery, characterization and development. Nat Rev Drug Discov. 9:628–642. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gumuslu E, Mutlu O, Sunnetci D, Ulak G, Celikyurt IK, Cine N, Akar F, Savlı H and Erden F: The antidepressant agomelatine improves memory deterioration and upregulates CREB and BDNF gene expression levels in unpredictable chronic mild stress (UCMS)-exposed mice. Drug Target Insights. 8:11–21. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, Geddes JR and McShane R: Ketamine infusions for treatment resistant depression: A series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 28:536–544. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Aguilar-Valles A, De Gregorio D, Matta-Camacho E, Eslamizade MJ, Khlaifia A, Skaleka A, Lopez-Canul M, Torres-Berrio A, Bermudez S, Rurak GM, et al: Antidepressant actions of ketamine engage cell-specific translation via eIF4E. Nature. 590:315–319. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Corriger A and Pickering G: Ketamine and depression: A narrative review. Drug Des Devel Ther. 13:3051–3067. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Palmer EC, Binns LN and Carey H: Levomilnacipran: A new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder. Ann Pharmacother. 48:1030–1039. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Krause-Sorio B, Kilpatrick L, Siddarth P, Ercoli L, Laird KT, Aguilar-Faustino Y, Milillo MM, Narr KL and Lavretsky H: Cortical thickness increases with levomilnacipran treatment in a pilot randomised double-blind placebo-controlled trial in late-life depression. Psychogeriatrics. 20:140–148. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Anthonis E and Sienaert P: Farmacotherapeutic treatment of psychotic depression: A review. Tijdschr Psychiatr. 63:358–365. 2021.(In Dutch). PubMed/NCBI | |
|
Greer TL, Grannemann BD, Chansard M, Karim AI and Trivedi MH: Dose-dependent changes in cognitive function with exercise augmentation for major depression: Results from the TREAD study. Eur Neuropsychopharmacol. 25:248–256. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Reutfors J, Brenner P, Brody B, Wray H, Andersen M and Brandt L: A post-authorization safety study of quetiapine as antidepressant treatment in Sweden: Nested case-control analyses of select outcomes. Drug Saf. 43:135–145. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Torales J, O'Higgins M, Castaldelli-Maia JM and Ventriglio A: The outbreak of COVID-19 coronavirus and its impact on global mental health. Int J Soc Psychiatry. 66:317–320. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Sensoy B, Gunes A and Ari S: Anxiety and depression levels in Covid-19 disease and their relation to hypertension. Clin Exp Hypertens. 43:237–241. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lai J, Ma S, Wang Y, Cai Z, Hu J, Wei N, Wu J, Du H, Chen T, Li R, et al: Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. JAMA Netw Open. 3:e2039762020. View Article : Google Scholar : PubMed/NCBI | |
|
Mahalakshmi AM, Ray B, Tuladhar S, Bhat A, Paneyala S, Patteswari D, Sakharkar MK, Hamdan H, Ojcius DM, Bolla SR, et al: Does COVID-19 contribute to development of neurological disease? Immun Inflamm Dis. 9:48–58. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Combe B, Balsa A, Sarzi-Puttini P, Tony HP, de la Torre I, Rogai V, Durand F, Witt S, Zhong J and Dougados M: Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib. Ann Rheum Dis. 78:1135–1138. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lipworth B, Kuo CR and Chan R: Emerging pharmacotherapy for COVID-19. J R Coll Physicians Edinb. 50:133–137. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Reder AT, Oger JF, Kappos L, O'Connor P and Rametta M: Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis. Mult Scler Relat Disord. 3:294–302. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Theoharides TC and Conti P: Dexamethasone for COVID-19? Not so fast. J Biol Regul Homeost Agents. 34:1241–1243. 2020.PubMed/NCBI | |
|
Menke A, Arloth J, Best J, Namendorf C, Gerlach T, Czamara D, Lucae S, Dunlop BW, Crowe TM, Garlow SJ, et al: Time-dependent effects of dexamethasone plasma concentrations on glucocorticoid receptor challenge tests. Psychoneuroendocrinology. 69:161–171. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shader RI: COVID-19 and depression. Clin Ther. 42:962–963. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Armitage R and Nellums LB: COVID-19 and the consequences of isolating the elderly. Lancet Public Health. 5:e2562020. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar S, Veldhuis A and Malhotra T: Neuropsychiatric and cognitive sequelae of COVID-19. Front Psychol. 12:5775292021. View Article : Google Scholar : PubMed/NCBI | |
|
Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis G and David AS: Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 7:611–627. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L, et al: Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 55:1027632020. View Article : Google Scholar : PubMed/NCBI | |
|
Tsamakis K, Mueller C, Tsirigotis P, Tsiptsios D, Tsamakis C, Charakopoulos E, Charalampous C, Spandidos DA, Douzenis A, Papageorgiou C, et al: Depression following graft-versus-host disease in a patient with acute lymphoblastic leukaemia: A case report. Mol Clin Oncol. 12:208–211. 2020.PubMed/NCBI | |
|
Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, Oltolini C, Castiglioni B, Tassan Din C, Boffini N, et al: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study. Lancet Rheumatol. 2:e325–e331. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, Tomelleri A, Baldissera E, Rovere-Querini P, Ruggeri A, et al: Efficacy and safety of tocilizumab in severe COVID-19 patients: A single-centre retrospective cohort study. Eur J Intern Med. 76:43–49. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gonda X, Pompili M, Serafini G, Carvalho AF, Rihmer Z and Dome P: The role of cognitive dysfunction in the symptoms and remission from depression. Ann Gen Psychiatry. 14:272015. View Article : Google Scholar : PubMed/NCBI | |
|
Martin V, Allaïli N, Euvrard M, Marday T, Riffaud A, Franc B, Mocaër E, Gabriel C, Fossati P, Lehericy S and Lanfumey L: Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in mice. Sci Rep. 8:459072017. View Article : Google Scholar : PubMed/NCBI | |
|
Yamada M and Yasuhara H: Clinical pharmacology of MAO inhibitors: Safety and future. Neurotoxicology. 25:215–221. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Andrade C: Selective serotonin reuptake inhibitor drug interactions in patients receiving statins. J Clin Psychiatry. 75:e95–e99. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Voican CS, Corruble E, Naveau S and Perlemuter G: Antidepressant-induced liver injury: A review for clinicians. Am J Psychiatry. 171:404–415. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nelson JC: A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry. 46:1301–1308. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Fagiolini A, Comandini A, Catena Dell'Osso M and Kasper S: Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 26:1033–1049. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB and Roth BL: N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 33:2303–2312. 2008. View Article : Google Scholar : PubMed/NCBIPubMed/NCBI | |
|
Ketter TA, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangell LB, George MS, Callahan AM, Hinton ML, Chao J and Post RM: Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol. 15:327–333. 1995. View Article : Google Scholar : PubMed/NCBI |
